Literature DB >> 17010368

The automated counting of spots for the ELISpot assay.

Natalie Hawkins1, Steve Self, Jon Wakefield.   

Abstract

An automated method for counting spot-forming units in the ELISpot assay is described that uses a statistical model fit to training data that is based on counts from one or more experts. The method adapts to variable background intensities and provides considerable flexibility with respect to what image features can be used to model expert counts. Point estimates of spot counts are produced together with intervals that reflect the degree of uncertainty in the count. Finally, the approach is completely transparent and "open source" in contrast to methods embedded in current commercial software. An illustrative application to data from a study of the reactivity of T-cells from healthy human subjects to a pool of immunodominant peptides from CMV, EBV and flu is presented.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17010368      PMCID： PMC1945247          DOI： 10.1016/j.jim.2006.08.005

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN： 0022-1759            Impact factor:   2.303


  9 in total

1.  Medicine. The need for a global HIV vaccine enterprise.

Authors:  Richard D Klausner; Anthony S Fauci; Lawrence Corey; Gary J Nabel; Helene Gayle; Seth Berkley; Barton F Haynes; David Baltimore; Chris Collins; R Gordon Douglas; Jose Esparza; Donald P Francis; N K Ganguly; Julie Louise Gerberding; Margaret I Johnston; Michel D Kazatchkine; Andrew J McMichael; Malegapuru W Makgoba; Giuseppe Pantaleo; Peter Piot; Yiming Shao; Edmund Tramont; Harold Varmus; Judith N Wasserheit
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

2.  Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.

Authors:  Michael G Hudgens; Steven G Self; Ya-Lin Chiu; Nina D Russell; Helen Horton; M Juliana McElrath
Journal:  J Immunol Methods       Date:  2004-05       Impact factor: 2.303

3.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

4.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

5.  HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.

Authors:  S Mazzoli; D Trabattoni; S Lo Caputo; S Piconi; C Blé; F Meacci; S Ruzzante; A Salvi; F Semplici; R Longhi; M L Fusi; N Tofani; M Biasin; M L Villa; F Mazzotta; M Clerici
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects.

Authors:  W C Goh; J Markee; R E Akridge; M Meldorf; L Musey; T Karchmer; M Krone; A Collier; L Corey; M Emerman; M J McElrath
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

9.  HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.

Authors:  S Rowland-Jones; J Sutton; K Ariyoshi; T Dong; F Gotch; S McAdam; D Whitby; S Sabally; A Gallimore; T Corrah
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440
  9 in total
  3 in total

1.  Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease.

Authors:  Tobias M Nowacki; Dominik Bettenworth; Matthias Ross; Jan Heidemann; Paul V Lehmann; Andreas Lügering
Journal:  Cells       Date:  2012-04-23       Impact factor: 6.600

2.  Towards standardized automated immunomonitoring: an automated ELISpot assay for safe and parallelized functionality analysis of immune cells.

Authors:  J C Neubauer; I Sébastien; A Germann; S C Müller; A Meyerhans; H von Briesen; H Zimmermann
Journal:  Cytotechnology       Date:  2016-11-28       Impact factor: 2.058

3.  A novel strategy for interpreting the T-SPOT.TB test results read by an ELISPOT plate imager.

Authors:  Tae Yeul Kim; Ho Eun Chang; Seong-Wook Lee; Soo Hyun Seo; Yun Ji Hong; Jeong Su Park; Kyoung Un Park
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.